menu
    • menu
    [{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of \u20ac35m","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Roche Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Ph.."}]

    Find Clinical Drug Pipeline Developments & Deals by Enthera Pharmaceuticals

    Menu

    Enthera Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ent001

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001

                            Details : Ent001 targets the TMEM219 ligand, IGFBP3, it is designed to bind to TMEM219 and prevent cell death and the inflammation in type 1 diabetes and several other autoimmune diseases.

                            Brand Name : Ent001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 07, 2023

                            Lead Product(s) : Ent001

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ent001

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Roche Venture Fund

                            Deal Size : $42.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m

                            Details : The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate.

                            Brand Name : Ent001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 28, 2021

                            Lead Product(s) : Ent001

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Roche Venture Fund

                            Deal Size : $42.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed

                            Enthera Pharmaceuticals

                            Italy arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ent001

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Sofinnova Partners

                            Deal Size : $33.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Enthera Pharmaceuticals Raises €28 Million in Series A Financing to Advance Restorative Therapy for Type 1 D...

                            Details : Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets.

                            Brand Name : Ent001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : Ent001

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Sofinnova Partners

                            Deal Size : $33.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth